{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T06:44:19Z","timestamp":1776581059563,"version":"3.51.2"},"reference-count":608,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"DOI":"10.1093\/eurheartj\/ehz455","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T02:34:48Z","timestamp":1567218888000},"page":"111-188","source":"Crossref","is-referenced-by-count":7439,"title":["2019 ESC\/EAS Guidelines for the management of dyslipidaemias:\n                    <i>lipid modification to reduce cardiovascular risk<\/i>"],"prefix":"10.1093","volume":"41","author":[{"given":"Fran\u00e7ois","family":"Mach","sequence":"first","affiliation":[]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[]},{"given":"Alberico L","family":"Catapano","sequence":"additional","affiliation":[]},{"given":"Konstantinos C","family":"Koskinas","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Casula","sequence":"additional","affiliation":[]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[]},{"given":"M John","family":"Chapman","sequence":"additional","affiliation":[]},{"given":"Guy G","family":"De Backer","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Brian A","family":"Ference","sequence":"additional","affiliation":[]},{"given":"Ian M","family":"Graham","sequence":"additional","affiliation":[]},{"given":"Alison","family":"Halliday","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[]},{"given":"Borislava","family":"Mihaylova","sequence":"additional","affiliation":[]},{"given":"Terje R","family":"Pedersen","sequence":"additional","affiliation":[]},{"given":"Gabriele","family":"Riccardi","sequence":"additional","affiliation":[]},{"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[]},{"given":"Marc S","family":"Sabatine","sequence":"additional","affiliation":[]},{"given":"Marja-Riitta","family":"Taskinen","sequence":"additional","affiliation":[]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[]},{"name":"ESC Scientific Document Group","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[]},{"given":"Wolfram","family":"Doehner","sequence":"additional","affiliation":[]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[]},{"given":"Bruna","family":"Gigante","sequence":"additional","affiliation":[]},{"given":"Meral","family":"Kayikcioglu","sequence":"additional","affiliation":[]},{"given":"Goran","family":"Krstacic","sequence":"additional","affiliation":[]},{"given":"Ekaterini","family":"Lambrinou","sequence":"additional","affiliation":[]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Josep","family":"Masip","sequence":"additional","affiliation":[]},{"given":"Philippe","family":"Moulin","sequence":"additional","affiliation":[]},{"given":"Steffen","family":"Petersen","sequence":"additional","affiliation":[]},{"given":"Anna Sonia","family":"Petronio","sequence":"additional","affiliation":[]},{"given":"Massimo Francesco","family":"Piepoli","sequence":"additional","affiliation":[]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[]},{"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[]},{"given":"Walter F","family":"Riesen","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[]},{"given":"Jean-Paul","family":"Schmid","sequence":"additional","affiliation":[]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[]},{"given":"Iain A","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[]},{"given":"Isabella","family":"Sudano","sequence":"additional","affiliation":[]},{"given":"Alexandros D","family":"Tselepis","sequence":"additional","affiliation":[]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[]},{"given":"Cecile","family":"Vindis","sequence":"additional","affiliation":[]},{"given":"Alexander","family":"Vonbank","sequence":"additional","affiliation":[]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[]},{"given":"Mislav","family":"Vrsalovic","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Luis","family":"Zamorano","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Konstantinos C","family":"Koskinas","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Casula","sequence":"additional","affiliation":[]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[]},{"given":"M","family":"John Chapman","sequence":"additional","affiliation":[]},{"given":"Guy G","family":"De Backer","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Brian A","family":"Ference","sequence":"additional","affiliation":[]},{"given":"Ian M","family":"Graham","sequence":"additional","affiliation":[]},{"given":"Alison","family":"Halliday","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[]},{"given":"Borislava","family":"Mihaylova","sequence":"additional","affiliation":[]},{"given":"Terje R","family":"Pedersen","sequence":"additional","affiliation":[]},{"given":"Gabriele","family":"Riccardi","sequence":"additional","affiliation":[]},{"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[]},{"given":"Marc S","family":"Sabatine","sequence":"additional","affiliation":[]},{"given":"Marja-Riitta","family":"Taskinen","sequence":"additional","affiliation":[]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Veronica","family":"Dean","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[]},{"given":"Chris P","family":"Gale","sequence":"additional","affiliation":[]},{"given":"Diederick","family":"Grobbee","sequence":"additional","affiliation":[]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[]},{"given":"Gerhard","family":"Hindricks","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Iung","sequence":"additional","affiliation":[]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[]},{"given":"Hugo A","family":"Katus","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[]},{"given":"Steffen","family":"Petersen","sequence":"additional","affiliation":[]},{"given":"Anna Sonia","family":"Petronio","sequence":"additional","affiliation":[]},{"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[]},{"given":"Iain A","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Sousa-Uva","sequence":"additional","affiliation":[]},{"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[]},{"given":"Djamaleddine","family":"Nibouche","sequence":"additional","affiliation":[]},{"given":"Parounak H","family":"Zelveian","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Siostrzonek","sequence":"additional","affiliation":[]},{"given":"Ruslan","family":"Najafov","sequence":"additional","affiliation":[]},{"given":"Philippe","family":"van de Borne","sequence":"additional","affiliation":[]},{"given":"Belma","family":"Pojskic","sequence":"additional","affiliation":[]},{"given":"Arman","family":"Postadzhiyan","sequence":"additional","affiliation":[]},{"given":"Lambros","family":"Kypris","sequence":"additional","affiliation":[]},{"given":"Jind\u0159ich","family":"\u0160pinar","sequence":"additional","affiliation":[]},{"given":"Mogens Lytken","family":"Larsen","sequence":"additional","affiliation":[]},{"given":"Hesham Salah","family":"Eldin","sequence":"additional","affiliation":[]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[]},{"given":"Timo E","family":"Strandberg","sequence":"additional","affiliation":[]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[]},{"given":"Rusudan","family":"Agladze","sequence":"additional","affiliation":[]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[]},{"given":"Loukianos","family":"Rallidis","sequence":"additional","affiliation":[]},{"given":"L\u00e1szl\u00f3","family":"Bajnok","sequence":"additional","affiliation":[]},{"given":"Thorbj\u00f6rn","family":"Gudj\u00f3nsson","sequence":"additional","affiliation":[]},{"given":"Vincent","family":"Maher","sequence":"additional","affiliation":[]},{"given":"Yaakov","family":"Henkin","sequence":"additional","affiliation":[]},{"given":"Michele Massimo","family":"Gulizia","sequence":"additional","affiliation":[]},{"given":"Aisulu","family":"Mussagaliyeva","sequence":"additional","affiliation":[]},{"given":"Gani","family":"Bajraktari","sequence":"additional","affiliation":[]},{"given":"Alina","family":"Kerimkulova","sequence":"additional","affiliation":[]},{"given":"Gustavs","family":"Latkovskis","sequence":"additional","affiliation":[]},{"given":"Omar","family":"Hamoui","sequence":"additional","affiliation":[]},{"given":"Rimvydas","family":"Slapikas","sequence":"additional","affiliation":[]},{"given":"Laurent","family":"Visser","sequence":"additional","affiliation":[]},{"given":"Philip","family":"Dingli","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Ivanov","sequence":"additional","affiliation":[]},{"given":"Aneta","family":"Boskovic","sequence":"additional","affiliation":[]},{"given":"Mbarek","family":"Nazzi","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Visseren","sequence":"additional","affiliation":[]},{"given":"Irena","family":"Mitevska","sequence":"additional","affiliation":[]},{"given":"Kjetil","family":"Retterst\u00f8l","sequence":"additional","affiliation":[]},{"given":"Piotr","family":"Jankowski","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Fontes-Carvalho","sequence":"additional","affiliation":[]},{"given":"Dan","family":"Gaita","sequence":"additional","affiliation":[]},{"given":"Marat","family":"Ezhov","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Foscoli","sequence":"additional","affiliation":[]},{"given":"Vojislav","family":"Giga","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[]},{"given":"Leopoldo Perez","family":"de Isla","sequence":"additional","affiliation":[]},{"given":"Emil","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[]},{"given":"Roger","family":"Lehmann","sequence":"additional","affiliation":[]},{"given":"Leila","family":"Abid","sequence":"additional","affiliation":[]},{"given":"Oner","family":"Ozdogan","sequence":"additional","affiliation":[]},{"given":"Olena","family":"Mitchenko","sequence":"additional","affiliation":[]},{"given":"Riyaz S","family":"Patel","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"2026021606221842800_ehz455-B1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B3","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe--epidemiological update 2015","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/HJR.0b013e32832b38a1","article-title":"SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies","volume":"16","author":"Cooney","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026021606221842800_ehz455-B5","volume-title":"Global Status Report on Noncommunicable Diseases 2014"},{"key":"2026021606221842800_ehz455-B6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.07.020","article-title":"Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians","volume":"54","author":"Cooney","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2213-8587(15)00081-9","article-title":"A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys","volume":"3","author":"Hajifathalian","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.109.852756","article-title":"Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?","volume":"122","author":"Cooney","year":"2010","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B9","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B10","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/2047487315588390","article-title":"Cardiovascular risk estimation in older persons: SCORE O.P","volume":"23","author":"Cooney","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B13","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2468-2667(18)30200-7","article-title":"The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort","volume":"3","author":"Foster","year":"2018","journal-title":"Lancet Public Health"},{"key":"2026021606221842800_ehz455-B14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7326\/0003-4819-156-6-201203200-00006","article-title":"Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study","volume":"156","author":"Kavousi","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026021606221842800_ehz455-B15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2015.05.007","article-title":"The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society","volume":"241","author":"Vlachopoulos","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B17","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jcmg.2017.01.029","article-title":"Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA","volume":"11","author":"Mortensen","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026021606221842800_ehz455-B19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.2018.4242","article-title":"Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"320","author":"Lin","year":"2018","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jacc.2015.01.017","article-title":"Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study","volume":"65","author":"Baber","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcmg.2016.08.012","article-title":"Plaque composition in the proximal superficial femoral artery and peripheral artery disease events","volume":"10","author":"McDermott","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026021606221842800_ehz455-B22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ehjci\/jex239","article-title":"Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans","volume":"19","author":"Sillesen","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021606221842800_ehz455-B23","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/eurheartj\/ehq235","article-title":"Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology","volume":"32","author":"Perrone-Filardi","year":"2011","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jama.2012.9630","article-title":"Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis","volume":"308","author":"Den Ruijter","year":"2012","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B25","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/eurheartj\/ehq189","article-title":"Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS)","volume":"31","author":"Lorenz","year":"2010","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jcct.2018.10.001","article-title":"Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"12","author":"Garg","year":"2018","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"2026021606221842800_ehz455-B27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jcmg.2017.04.014","article-title":"Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC\/AHA cholesterol management guidelines: a cost-effectiveness analysis","volume":"10","author":"Hong","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026021606221842800_ehz455-B28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/eurheartj\/ehx774","article-title":"Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study","volume":"39","author":"Cho","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B29","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.2016.17020","article-title":"Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis","volume":"316","author":"Kavousi","year":"2016","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B30","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(12)60441-3","article-title":"Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data","volume":"379","author":"Lorenz","year":"2012","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B32","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B33","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B34","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B38","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B39","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B40","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B41","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","article-title":"Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg\/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B42","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Boren","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"2026021606221842800_ehz455-B44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC Health Promotion Series","volume":"72","author":"Ference","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B45","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Di Angelantonio","year":"2012","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B46","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"2026021606221842800_ehz455-B47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"2026021606221842800_ehz455-B48","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B49","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B50","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B51","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B52","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B54","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B55","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B56","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/er.2014-1062","article-title":"Hypertriglyceridemia in the genomic era: a new paradigm","volume":"36","author":"Lewis","year":"2015","journal-title":"Endocr Rev"},{"key":"2026021606221842800_ehz455-B59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","article-title":"Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants","volume":"28","author":"Dron","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"2026021606221842800_ehz455-B60","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B61","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","article-title":"Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease","volume":"299","author":"Frikke-Schmidt","year":"2008","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B62","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B63","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B64","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B65","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B66","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Group","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/cdt.2017.01.01","article-title":"Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study","volume":"7","author":"Andrews","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026021606221842800_ehz455-B69","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B70","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"2026021606221842800_ehz455-B71","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B72","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B74","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B75","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B76","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B78","doi-asserted-by":"crossref","first-page":"e001696","DOI":"10.1161\/CIRCGEN.117.001696","article-title":"HPS2-THRIVE Collaborative Group. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study","volume":"11","author":"Parish","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"2026021606221842800_ehz455-B79","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/labmed\/lmx023","article-title":"Underestimation of low density lipoprotein-cholesterol with the Friedewald equation versus a direct homogenous low density lipoprotein-cholesterol assay","volume":"48","author":"Jialal","year":"2017","journal-title":"Lab Med"},{"key":"2026021606221842800_ehz455-B81","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","article-title":"Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications","volume":"62","author":"Martin","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B82","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/clinchem\/48.2.236","article-title":"Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation","volume":"48","author":"Nauck","year":"2002","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40200-017-0326-2","article-title":"LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations","volume":"16","author":"Razi","year":"2017","journal-title":"J\u00a0Diabetes Metab Disord"},{"key":"2026021606221842800_ehz455-B84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B85","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.117.030677","article-title":"Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy","volume":"137","author":"Sathiyakumar","year":"2018","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B86","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jacl.2017.05.005","article-title":"Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol &lt;70 mg\/dL compared with a novel low-density lipoprotein estimation method","volume":"11","author":"Whelton","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B87","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1373\/clinchem.2014.227710","article-title":"Validation of a proposed novel equation for estimating LDL cholesterol","volume":"60","author":"Meeusen","year":"2014","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2013.12.016","article-title":"Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group","volume":"233","author":"Langlois","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B89","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2012.08.022","article-title":"A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects","volume":"225","author":"Miida","year":"2012","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B90","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B91","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"2026021606221842800_ehz455-B92","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B93","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B94","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B95","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"Jorgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B96","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/157016111795495549","article-title":"Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement","volume":"9","author":"Kolovou","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"2026021606221842800_ehz455-B97","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157016111795495530","article-title":"Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis","volume":"9","author":"Mihas","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"2026021606221842800_ehz455-B98","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B99","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1373\/clinchem.2007.100941","article-title":"Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B","volume":"54","author":"Baca","year":"2008","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B100","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B101","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinbiochem.2017.11.007","article-title":"Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital","volume":"52","author":"Cartier","year":"2018","journal-title":"Clin Biochem"},{"key":"2026021606221842800_ehz455-B102","volume-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease","year":"2014"},{"key":"2026021606221842800_ehz455-B103","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","year":"2014","journal-title":"Heart"},{"key":"2026021606221842800_ehz455-B104","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/CIRCULATIONAHA.114.010001","article-title":"Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III)","volume":"130","author":"Doran","year":"2014","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B105","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.amjcard.2017.01.008","article-title":"Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up","volume":"119","author":"Harari","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B106","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.amjcard.2015.06.040","article-title":"Usefulness of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as predictors of cardiovascular disease in Chinese","volume":"116","author":"Gu","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B107","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjcard.2016.06.048","article-title":"Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease","volume":"118","author":"van den Berg","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B108","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1373\/clinchem.2010.154773","article-title":"Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population","volume":"57","author":"van Deventer","year":"2011","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B109","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.atherosclerosis.2012.08.039","article-title":"Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study","volume":"225","author":"Sniderman","year":"2012","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B111","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B112","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B113","first-page":"1769","article-title":"ESC Committee for Practice Guidelines Committees (CPG) 2008-2010 and 2010-2012 Committees. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B114","first-page":"1785","article-title":"2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk:","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B115","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B116","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol &lt;50 mg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B117","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/ijcp.12881","article-title":"Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date","volume":"70","author":"McCormack","year":"2016","journal-title":"Int J Clin Pract"},{"key":"2026021606221842800_ehz455-B118","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J\u00a0Hypertens"},{"key":"2026021606221842800_ehz455-B119","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B120","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B121","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin Chem"},{"key":"2026021606221842800_ehz455-B122","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2796.2006.01644.x","article-title":"Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B\/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies","volume":"259","author":"Thompson","year":"2006","journal-title":"J\u00a0Intern Med"},{"key":"2026021606221842800_ehz455-B123","doi-asserted-by":"crossref","first-page":"e000759","DOI":"10.1161\/JAHA.113.000759","article-title":"Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials","volume":"3","author":"Thanassoulis","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2026021606221842800_ehz455-B124","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjmed.2013.12.014","article-title":"Diets to prevent coronary heart disease 1957-2013: what have we learned?","volume":"127","author":"Dalen","year":"2014","journal-title":"Am J Med"},{"key":"2026021606221842800_ehz455-B126","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1161\/01.cir.0000437740.48606.d1","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Eckel","year":"2014","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B127","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinternmed.2009.38","article-title":"A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease","volume":"169","author":"Mente","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026021606221842800_ehz455-B128","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M13-1788","article-title":"Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis","volume":"160","author":"Chowdhury","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026021606221842800_ehz455-B129","doi-asserted-by":"crossref","first-page":"e1000252","DOI":"10.1371\/journal.pmed.1000252","article-title":"Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Mozaffarian","year":"2010","journal-title":"PLoS Med"},{"key":"2026021606221842800_ehz455-B130","doi-asserted-by":"crossref","first-page":"k2139","DOI":"10.1136\/bmj.k2139","article-title":"Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance","volume":"361","author":"Forouhi","year":"2018","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B131","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/eurheartj\/ehv595","article-title":"Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study","volume":"37","author":"Mozaffarian","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B132","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3945\/ajcn.116.134460","article-title":"Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults","volume":"104","author":"Chen","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B133","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.HYP.34.3.472","article-title":"Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group","volume":"34","author":"Moore","year":"1999","journal-title":"Hypertension"},{"key":"2026021606221842800_ehz455-B134","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1017\/S1368980013003169","article-title":"Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score","volume":"17","author":"Sofi","year":"2014","journal-title":"Public Health Nutr"},{"key":"2026021606221842800_ehz455-B135","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1080\/10408398.2015.1107021","article-title":"A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal?","volume":"57","author":"Grosso","year":"2017","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2026021606221842800_ehz455-B136","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B137","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMc1806491","article-title":"Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B138","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","article-title":"Health effects of trans-fatty acids: experimental and observational evidence","volume":"63","author":"Mozaffarian","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"2026021606221842800_ehz455-B139","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.numecd.2017.10.010","article-title":"A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease","volume":"27","author":"Clifton","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B141","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3945\/ajcn.115.109165","article-title":"Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies","volume":"102","author":"Hollaender","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B142","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2013.11.043","article-title":"Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease","volume":"232","author":"Gylling","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B143","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.plefa.2011.02.001","article-title":"A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials","volume":"85","author":"Musa-Veloso","year":"2011","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026021606221842800_ehz455-B144","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2018.05.015","article-title":"Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper","volume":"134","author":"Poli","year":"2018","journal-title":"Pharmacol Res"},{"key":"2026021606221842800_ehz455-B145","doi-asserted-by":"crossref","first-page":"e98611","DOI":"10.1371\/journal.pone.0098611","article-title":"A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B146","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B147","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.166.3.285","article-title":"Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials","volume":"166","author":"Nordmann","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026021606221842800_ehz455-B148","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/obr.12433","article-title":"Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis","volume":"17","author":"Zomer","year":"2016","journal-title":"Obes Rev"},{"key":"2026021606221842800_ehz455-B149","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3945\/ajcn.114.100305","article-title":"Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis","volume":"102","author":"Berger","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B150","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s13668-013-0064-0","article-title":"Dietary cholesterol and plasma lipoprotein profiles: randomized-controlled trials","volume":"2","author":"Griffin","year":"2013","journal-title":"Curr Nutr Rep"},{"key":"2026021606221842800_ehz455-B151","first-page":"CD003817","article-title":"Exercise for overweight or obesity","volume":"4","author":"Shaw","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B152","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1475-2891-12-147","article-title":"A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial","volume":"12","author":"Droste","year":"2013","journal-title":"Nutr J"},{"key":"2026021606221842800_ehz455-B153","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B154","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ajcn\/69.4.632","article-title":"Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis","volume":"69","author":"Yu-Poth","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B155","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1467-789X.2012.01021.x","article-title":"Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors","volume":"13","author":"Santos","year":"2012","journal-title":"Obes Rev"},{"key":"2026021606221842800_ehz455-B156","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0021-9150(02)00424-0","article-title":"Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects","volume":"167","author":"Rivellese","year":"2003","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B157","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"2026021606221842800_ehz455-B158","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nut.2013.08.014","article-title":"Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis","volume":"30","author":"Kelishadi","year":"2014","journal-title":"Nutrition"},{"key":"2026021606221842800_ehz455-B159","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI37385","article-title":"Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans","volume":"119","author":"Stanhope","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"2026021606221842800_ehz455-B160","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1017\/S0007114514002578","article-title":"Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials","volume":"112","author":"Gayet-Boyer","year":"2014","journal-title":"Br J Nutr"},{"key":"2026021606221842800_ehz455-B161","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ypmed.2008.10.010","article-title":"Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"48","author":"Kelley","year":"2009","journal-title":"Prev Med"},{"key":"2026021606221842800_ehz455-B162","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jacc.2010.09.073","article-title":"The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals","volume":"57","author":"Kastorini","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B163","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-7435(03)00110-5","article-title":"The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis","volume":"37","author":"Maeda","year":"2003","journal-title":"Prev Med"},{"key":"2026021606221842800_ehz455-B164","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B165","doi-asserted-by":"crossref","first-page":"g2272","DOI":"10.1136\/bmj.g2272","article-title":"Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys","volume":"348","author":"Micha","year":"2014","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B166","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1194\/jlr.P085522","article-title":"Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis","volume":"59","author":"Schwingshackl","year":"2018","journal-title":"J\u00a0Lipid Res"},{"key":"2026021606221842800_ehz455-B167","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B168","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2012.04.014","article-title":"Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I","volume":"164","author":"Huffman","year":"2012","journal-title":"Am Heart J"},{"key":"2026021606221842800_ehz455-B169","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B170","doi-asserted-by":"crossref","first-page":"d636","DOI":"10.1136\/bmj.d636","article-title":"Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies","volume":"342","author":"Brien","year":"2011","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B171","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc09-0266","article-title":"Effects of a plant-based high-carbohydrate\/high-fiber diet versus high-monounsaturated fat\/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients","volume":"32","author":"De Natale","year":"2009","journal-title":"Diabetes Care"},{"key":"2026021606221842800_ehz455-B172","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ajcn\/73.3.560","article-title":"Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women","volume":"73","author":"Liu","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B173","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3945\/ajcn.114.100461","article-title":"A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid\/lipoprotein risk factors for cardiovascular disease in young adults","volume":"101","author":"Stanhope","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"2026021606221842800_ehz455-B174","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/joim.12632","article-title":"Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity","volume":"282","author":"Taskinen","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"2026021606221842800_ehz455-B175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B176","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/jgs.14514","article-title":"Weight loss interventions in older adults with obesity: a systematic review of randomized controlled trials since 2005","volume":"65","author":"Batsis","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"2026021606221842800_ehz455-B177","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCULATIONAHA.108.191627","article-title":"Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention","volume":"119","author":"Harris","year":"2009","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B178","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-158-7-201304020-00003","article-title":"Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study","volume":"158","author":"Mozaffarian","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026021606221842800_ehz455-B179","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11886-016-0744-7","article-title":"How well can we control dyslipidemias through lifestyle modifications?","volume":"18","author":"Riccardi","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"2026021606221842800_ehz455-B180","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2468-2667(18)30135-X","article-title":"Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis","volume":"3","author":"Seidelmann","year":"2018","journal-title":"Lancet Public Health"},{"key":"2026021606221842800_ehz455-B181","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(18)31812-9","article-title":"Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study","volume":"392","author":"Dehghan","year":"2018","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B182","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.numecd.2007.10.004","article-title":"Non-pharmacological control of plasma cholesterol levels","volume":"18","author":"Poli","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B183","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B184","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B185","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/2047487317716500","article-title":"Food supplements with red yeast rice: more regulations are needed","volume":"24","author":"De Backer","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B186","first-page":"CD011472","article-title":"Dietary fibre for the primary prevention of cardiovascular disease","volume":"1","author":"Hartley","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B187","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.numecd.2016.11.122","article-title":"Joint position statement on \"Nutraceuticals for the treatment of hypercholesterolemia\" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA)","volume":"27","author":"Pirro","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B188","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1210\/jc.2004-2350","article-title":"Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations","volume":"91","author":"Dewell","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"2026021606221842800_ehz455-B189","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0009-9236(99)70139-6","article-title":"Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors","volume":"65","author":"Mas","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2026021606221842800_ehz455-B190","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00044011-200525110-00003","article-title":"Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients","volume":"25","author":"Reiner","year":"2005","journal-title":"Clin Drug Investig"},{"key":"2026021606221842800_ehz455-B191","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","article-title":"Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension","volume":"161","author":"Lan","year":"2015","journal-title":"J\u00a0Ethnopharmacol"},{"key":"2026021606221842800_ehz455-B192","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B193","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","article-title":"Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review","volume":"6","author":"Jacobson","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B194","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"2026021606221842800_ehz455-B196","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B197","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B198","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B199","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B200","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12265-014-9559-3","article-title":"Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia","volume":"7","author":"Sharma","year":"2014","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"2026021606221842800_ehz455-B201","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database","volume":"51","author":"Barter","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"2026021606221842800_ehz455-B202","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.CIR.0000141728.23033.B5","article-title":"High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial","volume":"110","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B203","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B204","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"2026021606221842800_ehz455-B206","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/1158822-S0-000000000-00000","article-title":"Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering","volume":"10","author":"Pedersen","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026021606221842800_ehz455-B207","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00392-006-0403-x","article-title":"Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis","volume":"95","author":"Genser","year":"2006","journal-title":"Clin Res Cardiol"},{"key":"2026021606221842800_ehz455-B208","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1161\/01.CIR.91.8.2274","article-title":"Cholesterol reduction yields clinical benefit. A new look at old data","volume":"91","author":"Gould","year":"1995","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B209","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.97.10.946","article-title":"Cholesterol reduction yields clinical benefit: impact of statin trials","volume":"97","author":"Gould","year":"1998","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B210","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B211","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials","volume":"104","author":"Mills","year":"2011","journal-title":"QJM"},{"key":"2026021606221842800_ehz455-B212","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","article-title":"Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants","volume":"170","author":"Ray","year":"2010","journal-title":"Arch Intern Med"},{"key":"2026021606221842800_ehz455-B213","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B214","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B215","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B216","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B217","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B218","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jchf.2013.12.007","article-title":"Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)","volume":"2","author":"Rogers","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026021606221842800_ehz455-B219","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B220","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B221","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B222","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B223","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B224","first-page":"CD007514","article-title":"Statins for the treatment of dementia","volume":"7","author":"McGuinness","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B225","first-page":"CD008623","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Eslami","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B226","doi-asserted-by":"crossref","first-page":"e1001310","DOI":"10.1371\/journal.pmed.1001310","article-title":"Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials","volume":"9","author":"Rahimi","year":"2012","journal-title":"PLoS Med"},{"key":"2026021606221842800_ehz455-B227","doi-asserted-by":"crossref","first-page":"d1250","DOI":"10.1136\/bmj.d1250","article-title":"Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials","volume":"342","author":"Rahimi","year":"2011","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B228","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMoa1507750","article-title":"Perioperative rosuvastatin in cardiac surgery","volume":"374","author":"Zheng","year":"2016","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B229","first-page":"CD008565","article-title":"Statins for women with polycystic ovary syndrome not actively trying to conceive","volume":"10","author":"Raval","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B230","first-page":"CD003160","article-title":"Statins for the prevention of dementia","volume":"1","author":"McGuinness","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B231","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B232","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B233","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B234","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B235","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B236","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026021606221842800_ehz455-B237","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the adverse event reporting system","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B238","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B239","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B240","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026021606221842800_ehz455-B241","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B242","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2026021606221842800_ehz455-B243","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","article-title":"FDA drug safety communications: a narrative review and clinical considerations for older adults","volume":"10","author":"Marcum","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"2026021606221842800_ehz455-B244","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"2026021606221842800_ehz455-B245","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"2026021606221842800_ehz455-B246","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","article-title":"Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes","volume":"329","author":"Vuppalanchi","year":"2005","journal-title":"Am J Med Sci"},{"key":"2026021606221842800_ehz455-B247","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B248","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B249","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B250","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B251","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"key":"2026021606221842800_ehz455-B252","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/CIRCULATIONAHA.111.055269","article-title":"Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis","volume":"124","author":"Hackam","year":"2011","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B253","first-page":"CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","volume":"1","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B254","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.amjcard.2005.09.110","article-title":"Effects of statins on renal function","volume":"97","author":"Agarwal","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B255","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1097\/01.ASN.0000138236.82706.EE","article-title":"Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells","volume":"15","author":"Sidaway","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"2026021606221842800_ehz455-B256","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.3.6.547","article-title":"Rosuvastatin safety: lessons from the FDA review and post-approval surveillance","volume":"3","author":"Davidson","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"2026021606221842800_ehz455-B257","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B258","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11886-013-0397-8","article-title":"Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy","volume":"15","author":"Wiklund","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"2026021606221842800_ehz455-B259","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1463-1326.2008.00917.x","article-title":"Combination statin-fibrate therapy: safety aspects","volume":"11","author":"Franssen","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2026021606221842800_ehz455-B260","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjcard.2007.07.057","article-title":"Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use","volume":"101","author":"Holoshitz","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B261","first-page":"415","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"2026021606221842800_ehz455-B262","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J\u00a0Intern Med"},{"key":"2026021606221842800_ehz455-B263","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B264","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40256-013-0037-0","article-title":"Role of colesevelam in combination lipid-lowering therapy","volume":"13","author":"Jones","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026021606221842800_ehz455-B265","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B266","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B267","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","year":"2010","journal-title":"Am Heart J"},{"key":"2026021606221842800_ehz455-B268","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B269","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","author":"Stitziel","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B270","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2174\/0929867323666160229114111","article-title":"Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases","volume":"23","author":"Pirillo","year":"2016","journal-title":"Curr Med Chem"},{"key":"2026021606221842800_ehz455-B271","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B272","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/2047487318766612","article-title":"A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes","volume":"25","author":"Khan","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B273","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","article-title":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials","volume":"39","author":"Koskinas","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B274","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijcard.2016.10.011","article-title":"The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials","volume":"227","author":"Mazidi","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026021606221842800_ehz455-B275","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/dme.12295","article-title":"Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review","volume":"31","author":"Ooi","year":"2014","journal-title":"Diabet Med"},{"key":"2026021606221842800_ehz455-B276","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0021-9681(83)90138-8","article-title":"Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial","volume":"36","year":"1983","journal-title":"J\u00a0Chronic Dis"},{"issue":"3","key":"2026021606221842800_ehz455-B277","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B278","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.1992.00400190041009","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators","volume":"152","year":"1992","journal-title":"Arch Intern Med"},{"key":"2026021606221842800_ehz455-B279","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.diabres.2013.12.033","article-title":"Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin","volume":"104","author":"He","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2026021606221842800_ehz455-B280","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"2026021606221842800_ehz455-B281","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","article-title":"Targeting PCSK9 for hypercholesterolemia","volume":"54","author":"Norata","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026021606221842800_ehz455-B282","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid lowering therapy and circulating PCSK9 concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"2026021606221842800_ehz455-B283","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10557-016-6655-4","article-title":"Clinical profile of statin intolerance in the phase 3 GAUSS-2 Study","volume":"30","author":"Cho","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026021606221842800_ehz455-B284","first-page":"CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"4","author":"Schmidt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B285","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021606221842800_ehz455-B286","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B287","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14779072.2017.1348231","article-title":"Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?","volume":"15","author":"Stein","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026021606221842800_ehz455-B288","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B289","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B290","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B291","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/M15-2994","article-title":"Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review","volume":"164","author":"Navarese","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026021606221842800_ehz455-B292","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/14740338.2014.932348","article-title":"Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data","volume":"13","author":"Cicero","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"2026021606221842800_ehz455-B293","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B294","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B295","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/dom.13235","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis","volume":"20","author":"Cao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026021606221842800_ehz455-B296","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/dc17-1464","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years","volume":"41","author":"de Carvalho","year":"2018","journal-title":"Diabetes Care"},{"key":"2026021606221842800_ehz455-B297","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B298","doi-asserted-by":"crossref","first-page":"752","DOI":"10.7326\/M16-0006","article-title":"Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents: a systematic review and meta-analysis","volume":"164","author":"Zhang","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026021606221842800_ehz455-B299","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B300","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B301","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B302","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B303","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11883-014-0467-4","article-title":"The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations","volume":"17","author":"Agarwala","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"2026021606221842800_ehz455-B304","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40256-014-0077-0","article-title":"Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials","volume":"14","author":"Li","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026021606221842800_ehz455-B305","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2026021606221842800_ehz455-B306","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B307","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B308","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B309","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B310","first-page":"839","volume-title":"Circulation","year":"1992"},{"key":"2026021606221842800_ehz455-B311","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B312","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2015.04.228","article-title":"Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials","volume":"191","author":"Ip","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026021606221842800_ehz455-B313","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B314","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"2026021606221842800_ehz455-B315","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B316","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B317","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2026021606221842800_ehz455-B318","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"2026021606221842800_ehz455-B319","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B320","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B321","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-modifying therapies and risk of pancreatitis: a meta-analysis","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B322","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/ATVBAHA.108.178228","article-title":"Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate","volume":"29","author":"Taskinen","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021606221842800_ehz455-B323","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B324","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B325","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B326","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B327","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacl.2017.10.012","article-title":"Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial","volume":"12","author":"Stroes","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B328","first-page":"CD003177","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"7","author":"Abdelhamid","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B329","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B330","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bmj.38755.366331.2F","article-title":"Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review","volume":"332","author":"Hooper","year":"2006","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B331","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione","volume":"105","author":"Marchioli","year":"2002","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B332","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026021606221842800_ehz455-B333","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B334","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/djt174","article-title":"Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial","volume":"105","author":"Brasky","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"2026021606221842800_ehz455-B335","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B336","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B337","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B338","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B339","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B340","first-page":"257","article-title":"Bempedoic acid (ETC-1002): a current review","volume":"36","author":"Saeed","year":"2018","journal-title":"Cardiol Clin"},{"key":"2026021606221842800_ehz455-B341","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B342","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B343","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B344","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B345","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B346","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"2026021606221842800_ehz455-B347","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.atherosclerosissup.2017.08.003","article-title":"Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Gouni-Berthold","year":"2017","journal-title":"Atherosclerosis Supp"},{"key":"2026021606221842800_ehz455-B348","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.atherosclerosis.2017.06.059","article-title":"The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS)","volume":"263","author":"Gaudet","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B349","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11883-017-0697-3","article-title":"ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen","volume":"19","author":"Rocha","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"2026021606221842800_ehz455-B350","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/CIRCRESAHA.116.308685","article-title":"Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity","volume":"119","author":"Didichenko","year":"2016","journal-title":"Circ Res"},{"key":"2026021606221842800_ehz455-B351","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"2026021606221842800_ehz455-B352","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B353","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2174\/0929867324666170616111647","article-title":"Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance","volume":"25","author":"Schreml","year":"2018","journal-title":"Curr Med Chem"},{"key":"2026021606221842800_ehz455-B354","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacl.2016.03.008","article-title":"Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia","volume":"10","author":"Maki","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B355","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B356","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.atherosclerosis.2014.09.026","article-title":"Combination therapy in dyslipidemia: where are we now?","volume":"237","author":"Catapano","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B357","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"2026021606221842800_ehz455-B358","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MOL.0000000000000270","article-title":"Combined hyperlipidemia: familial but not (usually) monogenic","volume":"27","author":"Brahm","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"2026021606221842800_ehz455-B359","doi-asserted-by":"crossref","first-page":"e1006078","DOI":"10.1371\/journal.pgen.1006078","article-title":"The contribution of GWAS loci in familial dyslipidemias","volume":"12","author":"Ripatti","year":"2016","journal-title":"PLoS Genet"},{"key":"2026021606221842800_ehz455-B360","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veerkamp","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021606221842800_ehz455-B361","doi-asserted-by":"crossref","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"2026021606221842800_ehz455-B362","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B363","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B364","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B365","year":"1999"},{"key":"2026021606221842800_ehz455-B366","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B367","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B368","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B369","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B370","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B371","first-page":"CD006401","article-title":"Statins for children with familial hypercholesterolemia","volume":"7","author":"Vuorio","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B372","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/2047487318781360","article-title":"Treatment of children with homozygous familial hypercholesterolaemia","volume":"25","author":"Reiner","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B373","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MED.0000000000000316","article-title":"Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder","volume":"24","author":"Koopal","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026021606221842800_ehz455-B374","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1194\/jlr.R800069-JLR200","article-title":"Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS","volume":"50","author":"Mahley","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"2026021606221842800_ehz455-B375","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MOL.0000000000000192","article-title":"Dysbetalipoproteinemia: an extreme disorder of remnant metabolism","volume":"26","author":"Marais","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"2026021606221842800_ehz455-B376","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrendo.2010.50","article-title":"Diagnosis and treatment of apolipoprotein B dyslipoproteinemias","volume":"6","author":"Sniderman","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"2026021606221842800_ehz455-B377","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia--current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2026021606221842800_ehz455-B378","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.molmed.2016.02.005","article-title":"Therapeutic targets of triglyceride metabolism as informed by human genetics","volume":"22","author":"Bauer","year":"2016","journal-title":"Trends Mol Med"},{"key":"2026021606221842800_ehz455-B379","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther"},{"key":"2026021606221842800_ehz455-B380","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/CIRCRESAHA.113.301464","article-title":"Apolipoprotein C-III: going back to the future for a lipid drug target","volume":"112","author":"Huff","year":"2013","journal-title":"Circ Res"},{"key":"2026021606221842800_ehz455-B381","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B382","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis"},{"key":"2026021606221842800_ehz455-B383","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pan.2012.05.002","article-title":"A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose","volume":"12","author":"Lindkvist","year":"2012","journal-title":"Pancreatology"},{"key":"2026021606221842800_ehz455-B384","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"2026021606221842800_ehz455-B385","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacl.2016.11.002","article-title":"Lysosomal acid lipase deficiency: a hidden disease among cohorts of familial hypercholesterolemia?","volume":"11","author":"Chora","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B386","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B387","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mhj.2003.1","article-title":"Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study","volume":"145","author":"Hague","year":"2003","journal-title":"Am Heart J"},{"key":"2026021606221842800_ehz455-B388","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1161\/01.CIR.96.12.4211","article-title":"Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"96","author":"Miettinen","year":"1997","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B389","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1007\/s00125-014-3344-3","article-title":"Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"57","author":"d'Emden","year":"2014","journal-title":"Diabetologia"},{"key":"2026021606221842800_ehz455-B390","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/humrep\/17.9.2307","article-title":"Myocardial infarction and third generation oral contraceptives: aggregation of recent studies","volume":"17","author":"Spitzer","year":"2002","journal-title":"Hum Reprod"},{"key":"2026021606221842800_ehz455-B391","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacc.2008.09.042","article-title":"Contraceptive hormone use and cardiovascular disease","volume":"53","author":"Shufelt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B392","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B393","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/eurheartj\/ehr364","article-title":"Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth?","volume":"33","author":"Rosengren","year":"2012","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B394","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention","volume":"19","year":"1998","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B395","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/eht368","article-title":"Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010","volume":"34","author":"Koopman","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B396","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B397","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.2014.10924","article-title":"Evaluation and treatment of older patients with hypercholesterolemia: a clinical review","volume":"312","author":"Strandberg","year":"2014","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B398","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/bmj.39241.630741.BE1","article-title":"Preventive health care in elderly people needs rethinking","volume":"335","author":"Mangin","year":"2007","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B399","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-016-0039-3","article-title":"Diabetes and its drivers: the largest epidemic in human history?","volume":"3","author":"Zimmet","year":"2017","journal-title":"Clin Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B400","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B401","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2337\/dc16-2388","article-title":"Patients with diabetes without significant angiographic coronary artery disease have the same risk of myocardial infarction as patients without diabetes in a real-world population receiving appropriate prophylactic treatment","volume":"40","author":"Olesen","year":"2017","journal-title":"Diabetes Care"},{"key":"2026021606221842800_ehz455-B402","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B403","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B404","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00125-012-2817-5","article-title":"Revisiting the links between glycaemia, diabetes and cardiovascular disease","volume":"56","author":"Sattar","year":"2013","journal-title":"Diabetologia"},{"key":"2026021606221842800_ehz455-B405","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S2213-8587(16)30057-2","article-title":"Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study","volume":"4","author":"Brownrigg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B406","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease: an update","volume":"126","author":"Despres","year":"2012","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B407","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/gutjnl-2016-312891","article-title":"Non-alcoholic fatty liver disease as driving force in coronary heart disease?","volume":"66","author":"Targher","year":"2017","journal-title":"Gut"},{"key":"2026021606221842800_ehz455-B408","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026021606221842800_ehz455-B409","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B410","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.amjcard.2017.08.008","article-title":"Relation between a simple lifestyle risk score and established biological risk factors for cardiovascular disease","volume":"120","author":"Levesque","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B411","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B412","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11883-016-0614-1","article-title":"Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?","volume":"18","author":"Taskinen","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"2026021606221842800_ehz455-B413","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/ATVBAHA.115.305614","article-title":"Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study","volume":"35","author":"Boren","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021606221842800_ehz455-B414","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"2026021606221842800_ehz455-B415","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2015.04.810","article-title":"Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals in Hungary","volume":"241","author":"Mark","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B416","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"2026021606221842800_ehz455-B417","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.numecd.2007.12.003","article-title":"Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance","volume":"18","author":"Annuzzi","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B418","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B419","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"2026021606221842800_ehz455-B420","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021606221842800_ehz455-B421","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","article-title":"Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes","volume":"2","author":"Elam","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B422","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"141","author":"Saha","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026021606221842800_ehz455-B423","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"2026021606221842800_ehz455-B424","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.numecd.2017.11.001","article-title":"Hypertriglyceridemia and omega-3 fatty acids: their often overlooked role in cardiovascular disease prevention","volume":"28","author":"Arca","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B425","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"2026021606221842800_ehz455-B426","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B427","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"key":"2026021606221842800_ehz455-B428","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.metabol.2013.10.002","article-title":"Type 1 diabetes, metabolic syndrome and cardiovascular risk","volume":"63","author":"Chillaron","year":"2014","journal-title":"Metabolism"},{"key":"2026021606221842800_ehz455-B429","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1365-2362.2001.00779.x","article-title":"Effect of acute exogenous hyperinsulinaemia on very low density lipoprotein subfraction composition in normal subjects","volume":"31","author":"Annuzzi","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"2026021606221842800_ehz455-B430","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B431","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehr035","article-title":"Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of &gt;40 000 patients","volume":"32","author":"Mills","year":"2011","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B432","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B433","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacl.2016.07.002","article-title":"The risks of statin use in pregnancy: a systematic review","volume":"10","author":"Karalis","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B434","doi-asserted-by":"crossref","first-page":"e006537","DOI":"10.1161\/JAHA.117.006537","article-title":"Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology\/European Atherosclerosis Society (ESC\/EAS) guidelines after acute coronary syndromes","volume":"6","author":"Gencer","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2026021606221842800_ehz455-B435","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamacardio.2016.3458","article-title":"Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction","volume":"1","author":"Kureshi","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B436","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/eurheartj\/ehx515","article-title":"Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014","volume":"38","author":"Szummer","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B437","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B438","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B439","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"113","author":"Navarese","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B440","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B441","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/2047487317708677","article-title":"Early, intensive statin treatment reduces \u2018hard\u2019 cardiovascular outcomes after acute coronary syndrome","volume":"24","author":"Schwartz","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B442","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B443","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.2018.2444","article-title":"Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial","volume":"319","author":"Berwanger","year":"2018","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B444","doi-asserted-by":"crossref","first-page":"e006901","DOI":"10.1161\/JAHA.117.006901","article-title":"Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"6","author":"Kato","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2026021606221842800_ehz455-B445","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B446","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B447","doi-asserted-by":"crossref","first-page":"e003201","DOI":"10.1161\/CIRCOUTCOMES.116.003201","article-title":"Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: results from the IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"10","author":"Pokharel","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026021606221842800_ehz455-B448","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B449","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B450","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B451","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B452","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/clc.23112","article-title":"Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial","volume":"41","author":"Koskinas","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026021606221842800_ehz455-B453","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B454","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/CIRCULATIONAHA.110.002451","article-title":"Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies","volume":"123","author":"Patti","year":"2011","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B455","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcin.2009.11.021","article-title":"Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial","volume":"3","author":"Kim","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"2026021606221842800_ehz455-B456","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.jacc.2009.07.005","article-title":"Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction","volume":"54","author":"Briguori","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B457","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B458","doi-asserted-by":"crossref","first-page":"e0168726","DOI":"10.1371\/journal.pone.0168726","article-title":"Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis","volume":"12","author":"Navarese","year":"2017","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B459","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B460","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"2026021606221842800_ehz455-B461","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1161\/STROKEAHA.113.001576","article-title":"Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment","volume":"44","author":"Merwick","year":"2013","journal-title":"Stroke"},{"key":"2026021606221842800_ehz455-B462","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/STROKEAHA.117.017343","article-title":"Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation","volume":"48","author":"Flint","year":"2017","journal-title":"Stroke"},{"key":"2026021606221842800_ehz455-B463","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B464","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J\u00a0Card Fail"},{"key":"2026021606221842800_ehz455-B465","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCULATIONAHA.106.625574","article-title":"Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study","volume":"115","author":"Khush","year":"2007","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B466","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B467","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B468","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B469","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/eurheartj\/ehv072","article-title":"The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials","volume":"36","author":"Preiss","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B470","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B471","doi-asserted-by":"crossref","first-page":"e0171168","DOI":"10.1371\/journal.pone.0171168","article-title":"No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials","volume":"12","author":"Al-Gobari","year":"2017","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B472","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","article-title":"Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF","volume":"17","author":"Feinstein","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026021606221842800_ehz455-B473","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","article-title":"The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis","volume":"70","author":"Bayes-Genis","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B474","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.jacc.2017.08.068","article-title":"Cholesterol and heart failure: is there an important connection?","volume":"70","author":"Francis","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B475","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B476","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2014.13959","article-title":"Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis","volume":"312","author":"Smith","year":"2014","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B477","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B478","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/hc4301.098249","article-title":"Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis","volume":"104","author":"Novaro","year":"2001","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B479","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B480","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B481","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2008.04.060","article-title":"Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg)","volume":"102","author":"Dichtl","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B482","first-page":"CD009571","article-title":"Statins for aortic valve stenosis","volume":"9","author":"Thiago","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B483","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.atherosclerosis.2016.01.023","article-title":"The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis","volume":"246","author":"Zhao","year":"2016","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B484","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.amjcard.2017.12.011","article-title":"Effect modifications of lipid-lowering therapy on progression of aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study)","volume":"121","author":"Greve","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B485","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.amjcard.2014.01.414","article-title":"Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)","volume":"113","author":"Arsenault","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B486","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.amjcard.2017.02.042","article-title":"Relation of intensity of statin therapy and outcomes after transcatheter aortic valve replacement","volume":"119","author":"Huded","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B487","doi-asserted-by":"crossref","first-page":"e001111","DOI":"10.1161\/JAHA.114.001111","article-title":"Insights into aortic sclerosis and its relationship with coronary artery disease","volume":"3","author":"Milin","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2026021606221842800_ehz455-B488","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026021606221842800_ehz455-B489","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2174\/1570161111311050013","article-title":"Acute coronary syndromes in patients with chronic kidney disease","volume":"11","author":"Franczyk-Skora","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"2026021606221842800_ehz455-B490","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B491","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s11255-013-0407-1","article-title":"The risk of atherosclerosis in patients with chronic kidney disease","volume":"45","author":"Olechnowicz-Tietz","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"2026021606221842800_ehz455-B492","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B493","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.acvd.2015.06.001","article-title":"Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention","volume":"108","author":"Loncar","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"2026021606221842800_ehz455-B494","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026021606221842800_ehz455-B495","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.03.007","article-title":"Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants","volume":"72","author":"Barylski","year":"2013","journal-title":"Pharmacol Res"},{"key":"2026021606221842800_ehz455-B496","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"5","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B497","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5500\/wjt.v6.i1.125","article-title":"Post-transplant dyslipidemia: mechanisms, diagnosis and management","volume":"6","author":"Agarwal","year":"2016","journal-title":"World J Transplant"},{"key":"2026021606221842800_ehz455-B498","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/2042018816641580","article-title":"Metabolic consequences of modern immunosuppressive agents in solid organ transplantation","volume":"7","author":"Bamgbola","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026021606221842800_ehz455-B499","doi-asserted-by":"crossref","first-page":"179434","DOI":"10.1155\/2015\/179434","article-title":"Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation","volume":"2015","author":"Numakura","year":"2015","journal-title":"Dis Markers"},{"key":"2026021606221842800_ehz455-B500","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1590\/0102-6720201600040008","article-title":"Dietary management for dyslipidemia in liver transplant recipients","volume":"29","author":"Pinto","year":"2016","journal-title":"Arq Bras Cir Dig"},{"key":"2026021606221842800_ehz455-B501","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1600-6143.2012.04084.x","article-title":"Dyslipidemia and its therapeutic challenges in renal transplantation","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"2026021606221842800_ehz455-B502","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026021606221842800_ehz455-B503","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.transproceed.2006.06.125","article-title":"New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?","volume":"38","author":"Deleuze","year":"2006","journal-title":"Transplant Proc"},{"key":"2026021606221842800_ehz455-B504","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"2026021606221842800_ehz455-B505","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10620-011-1817-5","article-title":"Higher tacrolimus blood concentration is related to hyperlipidemia in living donor liver transplantation recipients","volume":"57","author":"Li","year":"2012","journal-title":"Dig Dis Sci"},{"key":"2026021606221842800_ehz455-B506","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J\u00a0Lipid Res"},{"key":"2026021606221842800_ehz455-B507","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.0000151805.86933.35","article-title":"Drug therapy in the heart transplant recipient: part IV: drug-drug interactions","volume":"111","author":"Page","year":"2005","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B508","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/lt.21710","article-title":"Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia","volume":"15","author":"Almutairi","year":"2009","journal-title":"Liver Transpl"},{"key":"2026021606221842800_ehz455-B509","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/TP.0b013e318198d7d0","article-title":"The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin","volume":"87","author":"Shaw","year":"2009","journal-title":"Transplantation"},{"key":"2026021606221842800_ehz455-B510","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","article-title":"ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)","volume":"32","author":"Tendera","year":"2011","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B511","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1001\/archinte.163.18.2157","article-title":"Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease","volume":"163","author":"McDermott","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026021606221842800_ehz455-B512","first-page":"CD000123","article-title":"Lipid-lowering for peripheral arterial disease of the lower limb","volume":"4","author":"Aung","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021606221842800_ehz455-B513","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B514","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B515","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B516","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.amjcard.2005.05.070","article-title":"Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease","volume":"96","author":"Tedeschi-Reiner","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B517","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B518","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B519","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/01.ATV.0000245819.32762.cb","article-title":"Abdominal aortic aneurysm: pathogenesis and implications for management","volume":"26","author":"Golledge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021606221842800_ehz455-B520","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ejvs.2006.03.009","article-title":"Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?","volume":"32","author":"Paraskevas","year":"2006","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026021606221842800_ehz455-B521","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jvs.2004.01.004","article-title":"Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial","volume":"39","author":"Durazzo","year":"2004","journal-title":"J\u00a0Vasc Surg"},{"key":"2026021606221842800_ehz455-B522","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMoa0808207","article-title":"Fluvastatin and perioperative events in patients undergoing vascular surgery","volume":"361","author":"Schouten","year":"2009","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B523","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/eurheartj\/ehq452","article-title":"Statins and renovascular disease in the elderly: a population-based cohort study","volume":"32","author":"Hackam","year":"2011","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B524","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/2047487313519344","article-title":"Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study","volume":"22","author":"Subherwal","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis--an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B526","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.immuni.2017.09.008","article-title":"Monocyte-macrophages and T cells in atherosclerosis","volume":"47","author":"Tabas","year":"2017","journal-title":"Immunity"},{"key":"2026021606221842800_ehz455-B527","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejphar.2017.05.010","article-title":"Animal models of atherosclerosis","volume":"816","author":"Emini Veseli","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"2026021606221842800_ehz455-B528","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.52.4.561","article-title":"Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus","volume":"52","author":"Tillett","year":"1930","journal-title":"J\u00a0Exp Med"},{"key":"2026021606221842800_ehz455-B529","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/CIRCULATIONAHA.106.649939","article-title":"Prognostic significance of the Centers for Disease Control\/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease","volume":"115","author":"Sabatine","year":"2007","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B530","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B531","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B532","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B533","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B534","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B535","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B536","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1529-8817.2005.00210.x","article-title":"Association of common CRP gene variants with CRP levels and cardiovascular events","volume":"69","author":"Miller","year":"2005","journal-title":"Ann Hum Genet"},{"key":"2026021606221842800_ehz455-B537","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1016\/j.ijcard.2013.07.113","article-title":"High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy","volume":"168","author":"Koenig","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026021606221842800_ehz455-B538","first-page":"S0735","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B539","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","article-title":"Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins","volume":"25","author":"Arnaud","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021606221842800_ehz455-B540","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B541","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B542","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B543","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B544","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B545","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B546","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.lfs.2013.02.018","article-title":"Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein","volume":"92","author":"Barbosa","year":"2013","journal-title":"Life Sci"},{"key":"2026021606221842800_ehz455-B547","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/bcp.12905","article-title":"Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms","volume":"81","author":"Sahebkar","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2026021606221842800_ehz455-B548","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B549","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1538-7836.2009.03404.x","article-title":"Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)","volume":"7","author":"Ridker","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"2026021606221842800_ehz455-B550","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B551","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1160\/TH16-10-0814","article-title":"Therapeutic strategies for atherosclerosis and atherothrombosis: past, present and future","volume":"117","author":"Weber","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026021606221842800_ehz455-B552","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026021606221842800_ehz455-B553","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"2026021606221842800_ehz455-B554","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"2026021606221842800_ehz455-B555","doi-asserted-by":"crossref","first-page":"e0151587","DOI":"10.1371\/journal.pone.0151587","article-title":"High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort","volume":"11","author":"Clarke","year":"2016","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B556","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","article-title":"Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort","volume":"58","author":"Cederberg","year":"2015","journal-title":"Diabetologia"},{"key":"2026021606221842800_ehz455-B557","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","article-title":"Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B558","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/eurheartj\/ehx628","article-title":"European Society of Cardiology: cardiovascular disease statistics 2017","volume":"39","author":"Timmis","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B559","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021606221842800_ehz455-B560","doi-asserted-by":"crossref","first-page":"e13957","DOI":"10.1371\/journal.pone.0013957","article-title":"Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006","volume":"5","author":"Aspelund","year":"2010","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B561","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/eurheartj\/ehn554","article-title":"Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002","volume":"30","author":"Bjorck","year":"2009","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B562","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCOUTCOMES.113.000264","article-title":"Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008","volume":"6","author":"Pereira","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026021606221842800_ehz455-B563","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1186\/1471-2458-13-1135","article-title":"Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008","volume":"13","author":"Unal","year":"2013","journal-title":"BMC Public Health"},{"key":"2026021606221842800_ehz455-B564","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40273-015-0328-1","article-title":"Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries","volume":"34","author":"EunetHta Joint Action","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2026021606221842800_ehz455-B565","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"key":"2026021606221842800_ehz455-B566","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2105\/AJPH.2009.185652","article-title":"A framework for public health action: the health impact pyramid","volume":"100","author":"Frieden","year":"2010","journal-title":"Am J Public Health"},{"key":"2026021606221842800_ehz455-B567","doi-asserted-by":"crossref","first-page":"g1088","DOI":"10.1136\/bmj.g1088","article-title":"Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data","volume":"348","author":"Hotchkiss","year":"2014","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B568","doi-asserted-by":"crossref","first-page":"e41842","DOI":"10.1371\/journal.pone.0041842","article-title":"Which interventions offer best value for money in primary prevention of cardiovascular disease?","volume":"7","author":"Cobiac","year":"2012","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B569","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jval.2014.03.1722","article-title":"An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study","volume":"17","author":"Collins","year":"2014","journal-title":"Value Health"},{"key":"2026021606221842800_ehz455-B570","doi-asserted-by":"crossref","first-page":"e84445","DOI":"10.1371\/journal.pone.0084445","article-title":"A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries","volume":"9","author":"Mason","year":"2014","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B571","doi-asserted-by":"crossref","first-page":"e0118353","DOI":"10.1371\/journal.pone.0118353","article-title":"Comparing different policy scenarios to reduce the consumption of ultra-processed foods in UK: impact on cardiovascular disease mortality using a modelling approach","volume":"10","author":"Moreira","year":"2015","journal-title":"PLoS One"},{"key":"2026021606221842800_ehz455-B572","doi-asserted-by":"crossref","first-page":"e002837","DOI":"10.1136\/bmjopen-2013-002837","article-title":"Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland","volume":"3","author":"O'Keeffe","year":"2013","journal-title":"BMJ Open"},{"key":"2026021606221842800_ehz455-B573","doi-asserted-by":"crossref","first-page":"d4044","DOI":"10.1136\/bmj.d4044","article-title":"Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study","volume":"343","author":"Barton","year":"2011","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B574","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2105\/AJPH.2014.301868","article-title":"The cost-effectiveness of New York City's Safe Routes to School Program","volume":"104","author":"Muennig","year":"2014","journal-title":"Am J Public Health"},{"key":"2026021606221842800_ehz455-B575","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.amepre.2008.06.040","article-title":"Cost effectiveness of community-based physical activity interventions","volume":"35","author":"Roux","year":"2008","journal-title":"Am J Prev Med"},{"key":"2026021606221842800_ehz455-B576","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/2047487312441726","article-title":"Population-level changes to promote cardiovascular health","volume":"20","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B577","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1161\/CIRCULATIONAHA.110.968735","article-title":"Components of a cardioprotective diet: new insights","volume":"123","author":"Mozaffarian","year":"2011","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B578","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/heapro\/dam027","article-title":"Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions","volume":"22","author":"Dalziel","year":"2007","journal-title":"Health Promot Int"},{"key":"2026021606221842800_ehz455-B579","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/S0140-6736(17)30647-5","article-title":"Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial","volume":"389","author":"Ahern","year":"2017","journal-title":"Lancet"},{"key":"2026021606221842800_ehz455-B580","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10198-016-0851-9","article-title":"The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program","volume":"18","author":"Neumann","year":"2017","journal-title":"Eur J Health Econ"},{"key":"2026021606221842800_ehz455-B581","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/thx.2009.131631","article-title":"Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD","volume":"65","author":"Hoogendoorn","year":"2010","journal-title":"Thorax"},{"key":"2026021606221842800_ehz455-B582","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ijo.2010.246","article-title":"Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity","volume":"35","author":"Forster","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"2026021606221842800_ehz455-B583","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/CIRCULATIONAHA.109.891523","article-title":"Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes","volume":"121","author":"Chow","year":"2010","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B584","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15020","article-title":"The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review","volume":"15","author":"Loveman","year":"2011","journal-title":"Health Technol Assess"},{"key":"2026021606221842800_ehz455-B585","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10198-012-0424-5","article-title":"The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop","volume":"14","author":"Guerriero","year":"2013","journal-title":"Eur J Health Econ"},{"key":"2026021606221842800_ehz455-B586","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/eurheartj\/eht232","article-title":"Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study","volume":"35","author":"McConnachie","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B587","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1185\/03007990802144705","article-title":"Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men","volume":"24","author":"Peura","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2026021606221842800_ehz455-B588","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.117.027067","article-title":"Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke","volume":"136","author":"Heller","year":"2017","journal-title":"Circulation"},{"key":"2026021606221842800_ehz455-B589","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B590","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.38993.731725.BE","article-title":"Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people","volume":"333","author":"Mihaylova","year":"2006","journal-title":"BMJ"},{"key":"2026021606221842800_ehz455-B591","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"2026021606221842800_ehz455-B592","first-page":"723","article-title":"Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States","volume":"20","author":"Davies","year":"2017","journal-title":"J\u00a0Med Econ"},{"key":"2026021606221842800_ehz455-B593","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehm020","article-title":"Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin","volume":"28","author":"Lindgren","year":"2007","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B594","doi-asserted-by":"crossref","first-page":"e004648","DOI":"10.1161\/JAHA.116.004648","article-title":"Cost-effectiveness of intensifying lipid-lowering therapy with statins based on individual absolute benefit in coronary artery disease patients","volume":"6","author":"Stam-Slob","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2026021606221842800_ehz455-B595","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1177\/2047487316667784","article-title":"On Behalf Of The Euroaspire Investigators. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2026021606221842800_ehz455-B596","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1524-4733.2008.00447.x","article-title":"The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients","volume":"12","author":"Cherry","year":"2009","journal-title":"Value Health"},{"key":"2026021606221842800_ehz455-B597","first-page":"2473","article-title":"Comprehensive efforts to increase adherence to statin therapy","volume":"38","author":"Vonbank","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B598","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.atherosclerosis.2011.04.014","article-title":"Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases","volume":"217","author":"Corrao","year":"2011","journal-title":"Atherosclerosis"},{"key":"2026021606221842800_ehz455-B599","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1524-4733.2010.00774.x","article-title":"The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications","volume":"13","author":"Chapman","year":"2010","journal-title":"Value Health"},{"key":"2026021606221842800_ehz455-B600","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2026021606221842800_ehz455-B601","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jamacardio.2017.3656","article-title":"Cost-effectiveness of PCSK9 inhibitors: proof in the modeling","volume":"2","author":"Bonow","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B602","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B603","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021606221842800_ehz455-B604","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ehjcvp\/pvx010","article-title":"Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting","volume":"4","author":"Korman","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026021606221842800_ehz455-B605","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/eurheartj\/ehx710","article-title":"\u2018Highest risk-highest benefit\u2019 strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies","volume":"39","author":"Annemans","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021606221842800_ehz455-B606","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2026021606221842800_ehz455-B607","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial","volume":"318","author":"Kazi","year":"2017","journal-title":"JAMA"},{"key":"2026021606221842800_ehz455-B608","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0140-6736(08)60868-5","article-title":"EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial","volume":"371","author":"Wood","year":"2008","journal-title":"Lancet"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/1\/111\/66477601\/eurheartj_41_1_111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/1\/111\/66477601\/eurheartj_41_1_111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:23:44Z","timestamp":1771241024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/1\/111\/5556353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":608,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,8,31]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1,1]]},"published":{"date-parts":[[2019,8,31]]}}}